Abstract:Twenty-five to thirty percent of patients with node-negative breast cancer are expected to relapse following surgery, therefore great efforts have been made to identify new prognostic markers that could be useful in defining patients for additional therapy. The expression of MMP-2 and MMP-9 has been associated with high potential of metastasis in several human carcinomas including breast cancer. In the present study we examined the prognostic value of immunoreactive MMP-2/MMP-9 protein in 270 consecutive lymph node negative cases who received radical mastectomy or modified radical mastectomy. Among the patients, 211 cases received adjuvant endocrine therapy and/or adjuvant chemotherapy. Using immunohistochemical assay, we found that 56.7% of the resected tumors were positive for MMP-2 whereas 59.6% of the samples were positive for MMP-9. χ 2 test demonstrated a significant direct association between MMP-2 and MMP-9 ( p < 0.001); positive immunostaining of MMP-2 was significantly related to higher tumor grade ( p < 0.001) and larger tumor size ( p =0.012); positive immunostaining of MMP-9 was significantly related to higher tumor grade ( p =0.002). In univariate analysis, using Cox-proportional hazard model we found MMP-2, MMP-9 and the co-expression of MMPs (MMP2/MMP9) were significantly associated with patients' relapse free survival ( p =0.016, 0.015 and 0.013 respectively) but not overall survival ( p =0.122, 0.320 and 0.091 respectively). Log-rank test also showed that MMP-2, MMP-9 or the co-expression of MMP2/MMP9 was unfavorable prognostic factor for relapse free survival but not overall survival. In subgroup analysis, we found MMPs were more prognostic for patients with no adjuvant treatment than for patients with adjuvant therapy. In multivariate analysis, using Cox-proportional hazard model we found co-expression of MMPs, larger tumor size and higher tumor grade were unfavorable for relapse free survival ( p =0.038, 0.007 and 0.015 for each). We concluded that MMP-2 and MMP-2 are unfavorable prognostic factors in breast cancer patients. They might be potential predictive factor for adjuvant systemic therapy. The co-expression of MMP-2 and MMP-9 has significantly prognostic value in node-negative patients.

Expression of Matrix Metalloproteinase-2 in Lymph Node-Negative Breast Carcinoma and Its Clinical Value

Prognostic Value of Matrix Metalloproteinases (MMP-2 and MMP-9) in Patients with Lymph Node-Negative Breast Carcinoma

The expression of tumor metastasis suppressor gene KAI1 and matrix metalloproteinase 2 in breast cancer tissues

Relationship of MMP-2mRNA Expression with Clinical Pathological Features and Prognosis in Gastric Cancer

Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

Expression and Prognostic Value of Matrix Metalloproteinases-9 (MMP-9) in Lymph Node-Negative Breast Carcinoma

The Study of Expression of Matrix Metalloproteinases-2 in Patients with Colorectal Cancer

Expression of Matrix Metalloproteinase-9 and Their Correlation with Tumor Invasion, Metastasis in Gastric Carcinoma

Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

Detection of Matrix Metalloproteinase-2 and Microvessel Density in Breast Carcinoma Tissue

Prognostic Significance of MMP-2 and TIMP-2 Expression in Infiltrating Breast Cancer

EXPRESSION OF MATRIX METALLOPROTEINASE-2 IN LUNG SQUAMOUS CELL CARCINOMA

The Relationship Between Matrix Metalloproteinase-2 and Mast Cells in Breast Tumor

Correlation between MMP2 expression in lung cancer tissues and clinical parameters: a retrospective clinical analysis

Relationship between expression of MMP-2 and cervical lymph node micrometastasis in oral squamous cell carcinoma

The Relationship Between the Expression ofMetalloproteinase- 2 and Laryngeal Squamous Cell Carcinoma

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis.

The expression of MMP2 and MMP9 in endometrial carcinoma

The Expression of VEGF and MMP-2 in Non-Small Cell Lung Cancer and Their Association with Pathological Factors and Prognosis

Expression of Cytokeratin 19 and Matrix Metalloproteinase 2 Predicts Lymph Node Metastasis in Hepatocellular Carcinoma.